Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

Factors that may cause actual results to differ materially include market and other conditions, the risk that product candidates that appeared promising in early research and clinical trials do not ...

"Up until now, risk models in genomics have relied on broad categories that overlook the specific and unique genetic makeup of each individual," said Giordano Bottà, CEO of Allelica. "This innovation ...

Elon Musk is the entrepreneur behind Neuralink, SpaceX, and Tesla - as well as more recently, a staple in Donald Trump's ...

Research and development expenses were $11.4 million for the third quarter ended September 30, 2024, compared to $11.7 million for the comparable period in 2023. The decrease was primarily related to ...

November 12, 2024NeuroPace, Inc. beats earnings expectations. Reported EPS is $-0.19, expectations were $-0.27. Operator: ...

The government's own anti-extremism advisor has told ITV News there's a "risk" that more MPs could be killed without more ...

A poster presentation updating patient data from the INB-100 ... are described in greater detail in the section entitled ...

Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and ...

“She wouldn’t have been my choice for the picture on the ‘wanted’ poster,” James Cunningham ... but that’s a onetime cost,” ...

Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort ...

Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ETCompany ParticipantsMarissa Bych - Gilmartin GroupMaria Sainz ...